A rare type of B cell that naturally acts to dampen T cell immune responses could feasibly be exploited as a form of cell immunotherapy for autoimmune disorders, scientists report.
Researchers from the Clemson University College of Science and the Heinrich Heine University in Germany have developed new optical imaging techniques that may accelerate the field of structural biology.
New study data highlights how receptors for various drug therapies work inside cells.
Studies in mouse models have shown how reducing levels of tau, a protein linked with Alzheimer’s disease, could prevent core symptoms of autism spectrum disorder. Tau has never before been linked with autism, but results from the newly reported studies, by a team at the Gladstone Institute of Neurological Disease, suggest that tau reduction holds promise as a potential treatment for some forms of autism.
Firms' existing deal for Phase III-stage CKD anemia drug in U.S. broadened to Europe, Canada, China, Russia, Australia, and the Middle East. Akebia will receive $73 million upfront, $135 million in development funding, and up to $657 million in milestones.
The acquisition will bring to Gilead TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) indicated for the treatment of adults with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
Decision was prompted by news of tax break on profits from U.K.-owned IP.
Aratana, which is rapidly establishing itself as a leader in pet therapeutics, has obtained global rights to Advaxis’ ADXS-cHER2 for the treatment of osteosarcoma...
Combination cancer immunotherapy boosts the innate and adaptive immune responses to eradicate large, immunosuppressive tumors